Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morice, P.
Right arrow Articles by Castaigne, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morice, P.
Right arrow Articles by Castaigne, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:74-77, 2003
© 2003 European Society for Medical Oncology

Original Paper

Results of interval debulking surgery in advanced stage ovarian cancer: an exposed–non-exposed study

P. Morice1,+, D. Brehier-Ollive1, A. Rey2, D. Atallah1, C. Lhommé3, P. Pautier3, C. Pomel1, S. Camatte1, P. Duvillard4 and D. Castaigne1

Departments of 1 Surgery, 2 Biostatistics, 3 Medical Oncology and 4 Pathology, Institut Gustave Roussy, Villejuif, France

Received 11 March 2002; revised 3 June 2002; accepted 8 July 2002

Background:

To study the results of interval debulking surgery (IDS) in patients treated for ‘unresectable’ advanced stage ovarian cancer compared with primary debulking surgery (PDS) followed by chemotherapy.

Patients and methods:

An exposed–non-exposed study including a group of 34 patients who underwent an IDS and were matched to an historic control group of 34 patients treated with PDS.

Results:

Optimal cytoreductive surgery was achieved in 94% (32 out of 34) of patients in both groups. The rates of post-operative morbidity, blood transfusion and median length of hospitalisation were significantly reduced in the study (IDS) group, but survival did not differ in both groups.

Conclusions:

IDS in patients with advanced stage ovarian cancer offers the same chance of survival as PDS, but it is better tolerated.

Key words: induction chemotherapy, interval debulking surgery, ovarian cancer, unresectable tumour


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner
Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis
PNAS, October 14, 2003; 100(21): 12343 - 12348.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.